Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Lineage Biosciences

2014 FOUNDED
M&A STATUS
M&A LATEST DEAL TYPE
1 FINANCING ROUNDS
Description

Developer of an antibody discovery technology intended to profile antibody responses using sequencing of immunoglobulin genes. The company's technology provides deep analysis of antibodies generated by natural immune responses during infection, autoimmune disease, cancer, immunization and vaccination, enabling the medical industry to develop vaccines and to accelerate antibody discovery.

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Primary Industry
Other Pharmaceuticals and Biotechnology
Acquirer
Primary Office
  • 3183 Porter Drive
  • Palo Alto, CA 94304
  • United States

Lineage Biosciences Valuation and Funding

Deal Type Date Amount Post-Val Valuation/
EBITDA
Debt Status

This information is reserved for PitchBook Platform users. To explore Lineage Biosciences‘s full profile, request access.

Request full access to PitchBook

Lineage Biosciences Executive Team (1)

Name Title Board
Seat
Contact
Info
Bruce Hironaka President